145 related articles for article (PubMed ID: 34321315)
1. Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression.
Matsumoto R; Hamada S; Tanaka Y; Taguchi K; Yamamoto M; Masamune A
J Pharmacol Exp Ther; 2021 Oct; 379(1):33-40. PubMed ID: 34321315
[TBL] [Abstract][Full Text] [Related]
2. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
3. Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
Mukhopadhyay S; Goswami D; Adiseshaiah PP; Burgan W; Yi M; Guerin TM; Kozlov SV; Nissley DV; McCormick F
Cancer Res; 2020 Apr; 80(8):1630-1643. PubMed ID: 31911550
[TBL] [Abstract][Full Text] [Related]
4. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway.
Zhou Y; Zhou Y; Yang M; Wang K; Liu Y; Zhang M; Yang Y; Jin C; Wang R; Hu R
Redox Biol; 2019 Apr; 22():101131. PubMed ID: 30735911
[TBL] [Abstract][Full Text] [Related]
5. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis.
Hamada S; Taguchi K; Masamune A; Yamamoto M; Shimosegawa T
Carcinogenesis; 2017 Jun; 38(6):661-670. PubMed ID: 29240881
[TBL] [Abstract][Full Text] [Related]
7. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
8. Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells.
Samatiwat P; Prawan A; Senggunprai L; Kukongviriyapan V
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):601-12. PubMed ID: 25708948
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer.
D'Costa Z; Jones K; Azad A; van Stiphout R; Lim SY; Gomes AL; Kinchesh P; Smart SC; Gillies McKenna W; Buffa FM; Sansom OJ; Muschel RJ; O'Neill E; Fokas E
Cancer Res; 2017 Nov; 77(21):5952-5962. PubMed ID: 28765154
[TBL] [Abstract][Full Text] [Related]
10. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
11. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
[TBL] [Abstract][Full Text] [Related]
12. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine.
Duong HQ; Yi YW; Kang HJ; Hong YB; Tang W; Wang A; Seong YS; Bae I
Int J Oncol; 2014 Mar; 44(3):959-69. PubMed ID: 24366069
[TBL] [Abstract][Full Text] [Related]
14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
15. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
16. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer.
Ramu I; Buchholz SM; Patzak MS; Goetze RG; Singh SK; Richards FM; Jodrell DI; Sipos B; Ströbel P; Ellenrieder V; Hessmann E; Neesse A
EBioMedicine; 2019 Oct; 48():161-168. PubMed ID: 31597597
[TBL] [Abstract][Full Text] [Related]
17. CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-κB signaling pathway.
Zhang Z; Chen L; Zhao C; Gong Q; Tang Z; Li H; Tao J
Cell Biol Toxicol; 2023 Aug; 39(4):1549-1560. PubMed ID: 35913601
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
19. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Yin T; Zhang Z; Cao B; Duan Q; Shi P; Zhao H; Camara SN; Shen Q; Wang C
Oncotarget; 2016 Jun; 7(24):37192-37204. PubMed ID: 27177084
[TBL] [Abstract][Full Text] [Related]
20. Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells.
Duong HQ; You KS; Oh S; Kwak SJ; Seong YS
Antioxidants (Basel); 2017 Jul; 6(3):. PubMed ID: 28671577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
